Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00257530
Other study ID # DNDi-IMQ-05
Secondary ID
Status Completed
Phase Phase 3
First received November 22, 2005
Last updated June 11, 2008
Start date December 2005
Est. completion date June 2006

Study information

Verified date June 2008
Source Drugs for Neglected Diseases
Contact n/a
Is FDA regulated No
Health authority Peru: UPHC (Universidad Peruana Cayetano Heredia)Canada: McGill UniversitySwitzerland: Drugs for Neglected Diseases initiative
Study type Interventional

Clinical Trial Summary

This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our previous results, we hypothesize that lesions in patients who receive the combined treatment of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and produce less scarring than treatment with pentavalent antimony alone.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date June 2006
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria:

- Males/Females between 5 and 65 yrs

- CL diagnosis confirmed

- >4 weeks time disease

- no prior anti-leishmanial therapy for CL

- negative pregnancy test

- informed written consent or parent consent for <18yrs patients

Exclusion Criteria:

- >25cm2 lesion(s)

- >6 cutaneous lesions

- mucosal lesion

- previous exposure to Imiquimod or anti-leish treatment

- participation in another protocol within 30 days prior study

- other acute or chronic illness / medication that may interfere

- significant psychiatric illness

- anaphylaxis or severe allergic reaction to proposed drugs

- patients unlikely to cooperate

- concomitant infection

- pregnancy or breast feeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Imiquimod


Locations

Country Name City State
Peru UPCH Cusco
Peru IMT Alexander Von Humboldt Lima

Sponsors (1)

Lead Sponsor Collaborator
Drugs for Neglected Diseases

Country where clinical trial is conducted

Peru, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to healing
Primary Reduction of scaring
Secondary Safety (measured by AE reporting) during treatment and follow up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT01988909 - WR 279,396 for the Treatment of Cutaneous Leishmaniasis Phase 2
Enrolling by invitation NCT00737386 - Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank N/A
Enrolling by invitation NCT00840359 - Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Phase 2
Completed NCT00233545 - Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Phase 2
Completed NCT01462500 - Pharmacokinetics of Miltefosine in Children and Adults Phase 4
Completed NCT01011309 - A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Phase 2
Completed NCT01301924 - Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Phase 2/Phase 3
Not yet recruiting NCT02281669 - Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients N/A
Completed NCT01464242 - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT01790659 - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Phase 3
Completed NCT01050907 - Miltefosine to Treat Mucocutaneous Leishmaniasis Phase 2
Completed NCT04340128 - Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Phase 3
Terminated NCT00317629 - Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Phase 3
Completed NCT00351520 - Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Phase 3
Completed NCT01381055 - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Phase 2/Phase 3
Completed NCT01050777 - Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Phase 0
Completed NCT01380314 - Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Phase 2
Terminated NCT01380301 - Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony Phase 2
Completed NCT00703924 - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Phase 2
Completed NCT00344084 - Surveillance for Leishmaniasis Skin Lesions in Mali